±±¾©Ê¯ÓÍ»¯¹¤Ñ§Ôº2026ÄêÑо¿ÉúÕÐÉú½ÓÊÕµ÷¼Á¹«¸æ
²é¿´: 1135  |  »Ø¸´: 4

chenyimin_2008

Òø³æ (ÕýʽдÊÖ)

[ÇóÖú] ¶Ô¼×±½»ÇËáË÷À­·ÇÄáµÄÀí»¯ÐÔÖÊ ÒÑÓÐ1È˲ÎÓë

¸÷λÓÐĬ¿ËË÷ÒýÂð£¿ÄÜ·ñ°ïÎÒÕÒ϶Լױ½»ÇËáµÄÀí»¯ÐÔÖÊ£¬Ð»Ð»°¡£¡
»Ø¸´´ËÂ¥

» ²ÂÄãϲ»¶

» ±¾Ö÷ÌâÏà¹Ø¼ÛÖµÌùÍÆ¼ö£¬¶ÔÄúͬÑùÓаïÖú:

ÿÌì½ø²½Ò»µãµã
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû

³ÕÒÄ×ÓÆ¤

°æÖ÷ (ÎÄ̳¾«Ó¢)

ÀÏÆ¦

ÓÅÐã°æÖ÷ÓÅÐã°æÖ÷

¡¾´ð°¸¡¿Ó¦Öú»ØÌû

¸Ðл²ÎÓ룬ӦÖúÖ¸Êý +1
Title: p-Toluenesulfonic Acid
CAS Registry Number: 104-15-4
CAS Name: 4-Methylbenzenesulfonic acid
Additional Names: tosic acid
Molecular Formula: C7H8O3S
Molecular Weight: 172.20
Percent Composition: C 48.82%, H 4.68%, O 27.87%, S 18.62%
Line Formula: CH3C6H4SO3H
Literature References: Prepd by sulfonation of toluene with 96-100% H2SO4; when carried out at 75¡ã the compn of the reaction product is 75% para-, 19% ortho- and 6% meta-toluenesulfonic acid. Convenient lab prepn: L. F. Fieser, Experiments in Organic Chemistry (Boston, 3rd ed., 1955) p 144. The separation of toluene from petroleum fractions can be accomplished by sulfonation with H2SO4 at 60¡ã.
Properties: Monoclinic leaflets or prisms. Also reported as crystallizing with 1H2O or 4H2O. When anhydrous, mp 106-107¡ã. Metastable form, mp 38¡ã. bp20 140¡ã. bp0.1 185-187¡ã. Freely sol in water, about 67 g/100 ml. Sol in alc and ether.
Melting point: mp 106-107¡ã; mp 38¡ã
Boiling point: bp20 140¡ã; bp0.1 185-187¡ã

Derivative Type: Sodium salt
Molecular Formula: C7H7NaO3S
Molecular Weight: 194.18
Percent Composition: C 43.30%, H 3.63%, Na 11.84%, O 24.72%, S 16.51%
Properties: Orthorhombic plates, very sol in water.

CAUTION: Highly irritating to skin, mucous membranes.
Use: In dye chemistry; in manuf of oral antidiabetic drugs.
ÊØºòÔÚ·çÖеÄÄþ¾²¡£
2Â¥2015-11-26 10:14:59
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû
3Â¥2015-11-26 10:37:26
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû

chenyimin_2008

Òø³æ (ÕýʽдÊÖ)

ÒýÓûØÌû:
2Â¥: Originally posted by ³ÕÒÄ×ÓÆ¤ at 2015-11-25 14:14:59
Title: p-Toluenesulfonic Acid
CAS Registry Number: 104-15-4
CAS Name: 4-Methylbenzenesulfonic acid
Additional Names: tosic acid
Molecular Formula: C7H8O3S
Molecular Weight: 172.20
Percent Compo ...

лл£¬´ò´íÁË£¬ÊǶԼױ½»ÇËáË÷À­·ÇÄᣬ̫¸ÐлÁË
ÿÌì½ø²½Ò»µãµã
4Â¥2015-11-26 12:18:12
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû

³ÕÒÄ×ÓÆ¤

°æÖ÷ (ÎÄ̳¾«Ó¢)

ÀÏÆ¦

ÓÅÐã°æÖ÷ÓÅÐã°æÖ÷

ÒýÓûØÌû:
4Â¥: Originally posted by chenyimin_2008 at 2015-11-26 12:18:12
лл£¬´ò´íÁË£¬ÊǶԼױ½»ÇËáË÷À­·ÇÄᣬ̫¸ÐлÁË...

Title: Sorafenib
CAS Registry Number: 284461-73-0
CAS Name: 4-[4-[[[[4-Chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-2-pyridinecarboxamide
Additional Names: N-4-(Chloro-3-(trifluoromethyl)phenyl)-N¢-(4-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl)urea
Manufacturers' Codes: Bay-43-9006
Molecular Formula: C21H16ClF3N4O3
Molecular Weight: 464.82
Percent Composition: C 54.26%, H 3.47%, Cl 7.63%, F 12.26%, N 12.05%, O 10.33%
Literature References: Multiple kinase inhibitor targeting both RAF kinase and receptor tyrosine kinases that promote angiogensis. Prepn: B. Riedl et al., WO 0041698 (2000 to Bayer); eidem, US 03139605 (2003); D. Bankston et al., Org. Process Res. Dev. 6, 777 (2002). Structure-activity study: U. R. Khire et al., Bioorg. Med. Chem. Lett. 14, 783 (2004). Characterization of kinase inhibition: S. M. Wilhelm et al., Cancer Res. 64, 7099 (2004). Mechanism of action study: D. J. Panka et al., Cancer Res. 66, 1611 (2006). LC determn in serum: S. Afify et al., J. Chromatogr. B 809, 99 (2004). Clinical pharmacokinetics: H. Richly et al., Int. J. Clin. Pharmacol. Ther. 41, 620 (2003). Analysis of clinical safety and efficacy: D. Strumberg et al., Eur. J. Cancer 42, 548 (2006). Clinical evaluation and brief review: H. DeGrendele, Clin. Colorectal Cancer 3, 16-18 (2003). Review of clinical development: B. I. Rini, Expert Opin. Pharmacother. 7, 453-461 (2006).
Properties: White solid, mp 205.6¡ã.
Melting point: mp 205.6¡ã

Derivative Type: Tosylate
CAS Registry Number: 475207-59-1
Trademarks: Nexavar (Bayer)
Molecular Formula: C21H16ClF3N4O3.C7H8O3S
Molecular Weight: 637.03
Percent Composition: C 52.79%, H 3.80%, Cl 5.57%, F 8.95%, N 8.80%, O 15.07%, S 5.03%

Therap-Cat: Antineoplastic.
Keywords: Antineoplastic; Tyrosine Kinase Inhibitors.
ÊØºòÔÚ·çÖеÄÄþ¾²¡£
5Â¥2015-11-26 12:23:21
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû
Ïà¹Ø°æ¿éÌø×ª ÎÒÒª¶©ÔÄÂ¥Ö÷ chenyimin_2008 µÄÖ÷Ìâ¸üÐÂ
×î¾ßÈËÆøÈÈÌûÍÆ¼ö [²é¿´È«²¿] ×÷Õß »Ø/¿´ ×îºó·¢±í
[¿¼ÑÐ] 269ר˶Çóµ÷¼Á +9 ½ð¶÷±´ 2026-03-21 9/450 2026-03-27 11:25 by ÍõЦÓîÒ»¶¨ÊÇÑо
[¿¼ÑÐ] Ò»Ö¾Ô¸Ö£´ó085600£¬310·ÖÇóµ÷¼Á +5 Àîäì¿É 2026-03-26 5/250 2026-03-27 11:14 by ²»³Ôô~µÄ؈
[¿¼ÑÐ] 0856²ÄÁÏר˶353Çóµ÷¼Á +9 NIFFFfff 2026-03-20 9/450 2026-03-27 10:13 by dick_runner
[¿¼ÑÐ] °²»Õ´óѧר˶ÉúÎïÓëҽҩרҵ(086000)324·Ö£¬Ó¢ÓïÒѹýËÄÁù¼¶£¬Áù¼¶521£¬Çóµ÷¼Á +3 ÃÀζ¿ÉÀÖ¼¦³á 2026-03-26 3/150 2026-03-27 08:46 by hxsm
[¿¼ÑÐ] 359Çóµ÷¼Á +4 ÍõÁ˸öéª 2026-03-25 4/200 2026-03-27 08:43 by ²»³Ôô~µÄ؈
[¿¼ÑÐ] 351Çóµ÷¼Á +4 Âó¿Ë°¢ÀÚ 2026-03-24 4/200 2026-03-27 00:32 by wxiongid
[¿¼ÑÐ] 342Çóµ÷¼Á +3 ¼ÓÓÍaÀîzs 2026-03-26 3/150 2026-03-27 00:29 by wxiongid
[¿¼ÑÐ] 071000ÉúÎïѧÇóµ÷¼Á£¬³õÊԳɼ¨343 +6 ССÌðÃæÍÅ 2026-03-25 6/300 2026-03-26 23:01 by ²»³Ôô~µÄ؈
[¿¼ÑÐ] Ò»Ö¾Ô¸»ªÀí£¬ÊýÒ»Ó¢Ò»285ÇóAÇøµ÷¼Á +8 AZMK 2026-03-25 10/500 2026-03-26 22:37 by ѧԱ8dgXkO
[¿¼ÑÐ] 266·ÖÇó²ÄÁÏ»¯¹¤Ò±½ð¿óÒµµÈרҵµÄµ÷¼Á +3 ÍÛºôºßºôºß 2026-03-26 3/150 2026-03-26 19:16 by JourneyLucky
[¿¼ÑÐ] »úеѧ˶310·Ö£¬ÊýÒ»Ó¢Ò»£¬Ò»Ö¾Ô¸211±¾¿ÆË«·ÇÕÒµ÷¼ÁÐÅÏ¢ +3 @357 2026-03-25 3/150 2026-03-26 16:34 by by.MENG
[¿¼ÑÐ] 263Çóµ÷¼Á +6 yqdszhdap£­ 2026-03-22 10/500 2026-03-26 13:11 by ¹«èªåÐÒ£
[¿¼ÑÐ] ¿¼Ñе÷¼Á +6 À´ºÃÔËÀ´À´À´ 2026-03-21 7/350 2026-03-25 22:43 by 418490947
[¿¼ÑÐ] ÍøÂç¿Õ¼ä°²È«0839Õе÷¼Á +4 w320357296 2026-03-25 6/300 2026-03-25 17:59 by 255671
[¿¼ÑÐ] 347Çóµ÷¼Á +4 L when 2026-03-25 4/200 2026-03-25 13:37 by cocolv
[¿¼ÑÐ] Çóµ÷¼Á +6 ÑÐÑУ¬½Óµç»° 2026-03-24 7/350 2026-03-24 17:01 by barlinike
[¿¼ÑÐ] 300Çóµ÷¼Á£¬²ÄÁÏ¿ÆÑ§Ó¢Ò»Êý¶þ +5 leaflight 2026-03-24 5/250 2026-03-24 16:25 by laoshidan
[¿¼ÑÐ] Ò»Ö¾Ô¸ÖØÇì´óѧ085700×ÊÔ´Óë»·¾³£¬×Ü·Ö308Çóµ÷¼Á +7 īīĮ 2026-03-23 8/400 2026-03-23 20:36 by Creta
[¿¼ÑÐ] 070300£¬Ò»Ö¾Ô¸±±º½320Çóµ÷¼Á +3 Jerry0216 2026-03-22 5/250 2026-03-23 09:16 by ¡£¡£ÌÃÌÃ
[¿¼ÑÐ] 330Çóµ÷¼Á0854 +3 assdll 2026-03-21 3/150 2026-03-21 13:01 by ²«»÷518
ÐÅÏ¢Ìáʾ
ÇëÌî´¦ÀíÒâ¼û